---
title: "Dexcom (DXCM) Gets a Buy from Jefferies"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275916801.md"
description: "Jefferies analyst Matthew Taylor has maintained a Buy rating on Dexcom (DXCM) with a price target of $112.00, while the stock closed at $68.20. The analyst consensus is a Strong Buy with an average price target of $90.33, indicating a potential upside of 32.45%. BTIG also supports a Buy rating with a target of $85.00. Taylor has an average return of 7.2% and a 55.90% success rate on his recommendations."
datetime: "2026-02-13T14:35:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275916801.md)
  - [en](https://longbridge.com/en/news/275916801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275916801.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275916801.md) | [English](https://longbridge.com/en/news/275916801.md)


# Dexcom (DXCM) Gets a Buy from Jefferies

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Dexcom, with a price target of $112.00. The company’s shares closed yesterday at $68.20.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, Dexcom, and Insulet. According to TipRanks, Taylor has an average return of 7.2% and a 55.90% success rate on recommended stocks.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $90.33, a 32.45% upside from current levels. In a report released today, BTIG also maintained a Buy rating on the stock with a $85.00 price target.

### 相關股票

- [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-HK/quote/XHE.US.md)
- [DexCom (DXCM.US)](https://longbridge.com/zh-HK/quote/DXCM.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-HK/quote/IHI.US.md)

## 相關資訊與研究

- [BUZZ-MiniMed rises as FDA clears smartphone‑controlled insulin pump](https://longbridge.com/zh-HK/news/279614092.md)
- [Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity](https://longbridge.com/zh-HK/news/279446168.md)
- [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/zh-HK/news/279451162.md)
- [Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus](https://longbridge.com/zh-HK/news/279245032.md)
- [10:10 ETPicarro Launches PI2124 Hydrogen Peroxide Analyzer to Improve VHP Monitoring in Pharmaceutical Manufacturing](https://longbridge.com/zh-HK/news/279619247.md)